|
|||||
|
|
Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant |
|
| Authors: | Wilbur H. Chen Lisa A. Jackson Kathryn M. Edwards Wendy A. Keitel Heather Hill Diana L. Noah C. Buddy Creech Shital M. Patel Brian Mangal Karen L. Kotloff |
| Affiliation: | aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA;bGroup Health Research Institute, Seattle, Washington, USA;cVanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, Nashville, Tennessee, USA;dBaylor College of Medicine, Houston, Texas, USA;eEMMES Corporation, Rockville, Maryland, USA;fSouthern Research, Birmingham, Alabama, USA |
| Abstract: | The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to 1 year after vaccination. |
| Keywords: | |